Stratos Wealth Advisors LLC grew its holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 40.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,059 shares of the company’s stock after acquiring an additional 3,778 shares during the quarter. Stratos Wealth Advisors LLC’s holdings in VanEck Pharmaceutical ETF were worth $1,241,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Comerica Bank increased its holdings in shares of VanEck Pharmaceutical ETF by 39.4% in the first quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after acquiring an additional 378 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of VanEck Pharmaceutical ETF by 85.0% during the second quarter. Renaissance Technologies LLC now owns 25,900 shares of the company’s stock worth $2,369,000 after buying an additional 11,902 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of VanEck Pharmaceutical ETF by 1.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 160,039 shares of the company’s stock worth $14,641,000 after buying an additional 2,694 shares during the period. CWM LLC acquired a new position in shares of VanEck Pharmaceutical ETF during the second quarter worth about $55,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in shares of VanEck Pharmaceutical ETF during the second quarter worth about $211,000.
VanEck Pharmaceutical ETF Price Performance
PPH stock opened at $94.67 on Monday. The stock has a market capitalization of $728.01 million, a P/E ratio of 21.04 and a beta of 0.72. The business has a 50-day moving average of $96.23 and a 200-day moving average of $92.40. VanEck Pharmaceutical ETF has a fifty-two week low of $74.05 and a fifty-two week high of $99.51.
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- Best Aerospace Stocks Investing
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What Does a Stock Split Mean?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Invest in the Best Canadian Stocks
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.